Mirvie RNA test aims to predict pregnancy complications

A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

A recent study reveals associations between concomitant histological fetal inflammatory response and adverse neonatal outcomes, urging further investigation into implications.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.

Discover the findings from a recent study highlighting the need to enhance vaccination rates among pregnant individuals living with HIV, shedding light on key factors influencing vaccine receipt.